A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier.
Int J Nanomedicine
; 16: 1051-1066, 2021.
Article
em En
| MEDLINE
| ID: mdl-33603368
ABSTRACT
BACKGROUND:
This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer.METHODS:
Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined.RESULTS:
The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery.CONCLUSION:
The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Portadores de Fármacos
/
Neoplasias do Colo do Útero
/
Sistemas de Liberação de Medicamentos
/
Proteínas de Ciclo Celular
/
Proteínas Adaptadoras de Transdução de Sinal
/
Terapia de Alvo Molecular
/
Fenômenos Magnéticos
/
RNA Longo não Codificante
/
Oxaliplatina
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Int J Nanomedicine
Ano de publicação:
2021
Tipo de documento:
Article